The healthcare investment news flow was relatively quiet this week, but a couple of transactions stand out for what they say about the importance of scale, geographic expansion and platform building.
Hygie31’s acquisition of a majority stake in Ireland’s Navi Group is interesting as the French healthcare group looks to extend its footprint into English-speaking Europe. Meanwhile, Apposite Capital-backed HCML is continuing to build out its occupational health platform with the acquisition of Corazon Health.
English-speaking target
France-based Hygie31 has acquired a majority stake in Navi Group, Ireland’s leading independent managed pharmacy services platform.
The transaction gives Hygie31 an entry into Ireland after establishing a presence in France, Spain and Italy. The group is affiliated with more than 3,900 independent pharmacies across those markets, representing combined turnover of around €5bn.
Navi brings scale of its own. Founded in 2009, it works with more than 600 pharmacies, representing almost 30% of the Irish market, and generates around €700m in business volume through its platforms. It also operates an international pharmaceutical wholesale business.
That combination gives Hygie31 both an established position in Ireland and a potential platform from which to pursue further expansion, particularly into the UK and other English-speaking markets.
The deal is about more than entering another European market. It extends a strategy of building scale across fragmented pharmacy markets while bringing together purchasing power, expertise and managed pharmacy services.
Hygie31 was acquired by Latour Capital, alongside minority investor Bpifrance, in 2022.
HCML builds OH platform
In the UK, Apposite Capital-backed HCML has acquired Corazon Health, strengthening its position in occupational health (OH).
Corazon provides OH services including new starter health assessments, management referrals, health surveillance and employee wellbeing programmes, drawing on 20 years of clinical experience.
The acquisition adds specialist occupational health capability to HCML’s broader offering across health, wellbeing, case management, rehabilitation and treatment services for corporate, legal, insurance and private medical insurance markets.
It also continues a clear buy-and-build strategy. HCML has previously acquired ILS in 2025, CA Case Management in 2023 and healthcare rm in 2022, following Apposite Capital’s acquisition of the business in 2021.
The Corazon transaction is another step in developing a broader platform rather than simply adding individual services. Combining HCML’s scale with Corazon’s specialist occupational health capabilities is intended to support further growth in a market where employers are increasingly focused on workplace health.
Other deals on our radar
Elsewhere, Medu Group, the Norway-based medical equipment distributor backed by Serendipity Partners, acquired Medical Scandinavia, strengthening its position in Denmark. The transaction is Medu’s twelfth acquisition.
Sweden-based AddLife acquired Portuguese laboratory equipment distributor Unicam Sistemas Analíticos, adding to its advanced laboratory technology offering. And listed Danish medtech company Ambu acquired US imaging and reporting specialist TIMS Medical for an upfront payment of US$45m, with up to a further US$20m in milestone payments.
In life sciences, HealthCap invested in Swedish health informatics company AMRA Medical, whose MRI-based technology provides quantitative biomarkers for fat and muscle analysis. Sanofi and German specialty pharma company Cheplapharm also announced a proposed partnership involving 20 mature medicines and three manufacturing sites, with Sanofi taking a 26.4% stake in Cheplapharm.
The week also brought further evidence of healthcare businesses investing in their platforms and capabilities. Medartis acquired the MARC Institute in Florida to establish its first US surgical education centre, while Germany’s GPNZ and Mydent combined their dental practice networks to create a group of around 30 locations.
